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Introduction
S-nitrosothiols (RSNOs) may serve as a reservoir of nitric oxide (NO) in biological systems and represent a class of NO donor with many potential clinical uses [1] . The potent and selective anti-platelet activity of some of these compounds has suggested that they may be particularly useful as anti-thrombotic agents [2] .
RSNOs produce antiplatelet activity either by releasing NO and stimulating guanylyl cyclase, or via cyclic GMP-independent mechanisms [3] . S-nitrosoglutathione (GSNO) releases NO only slowly, nevertheless it has the ability rapidly to inhibit platelet aggregation, in part through cyclic GMP-independent mechanisms [4] . Several studies have reported delivery of NO into cells via transnitrosation reactions, which involve transfer of NO + from one thiol to another [5] [6] [7] . For protein RSNOs (such as Snitrosoalbumin) to mediate platelet inhibition, prior exchange of NO onto a low molecular weight thiol appears necessary [8, 9] . Free thiols are available on the platelet surface itself [10, 11] and S-nitrosation of these thiols may be a further possible pathway of anti-platelet action. However the relatively unfavourable kinetics of transnitrosation reactions [12] suggest that some enzyme mediated system is required for the process to occur sufficiently rapidly to mediate signalling events.
A number of studies have documented the existence of enzyme-catalysed systems that facilitate delivery of NO from RSNO into cells, either by cell mediated metabolism or via amino acid transport systems [13] . These may be important both for mediating RSNO bioactivity and for enabling cells to deal with nitrosative stress during periods of 6 long-term exposure [14, 15] . For membrane-impermeable molecules such as GSNO, a cell surface enzyme such as γ-glutamyl transpeptidase (γ-GT) or protein disulphide isomerase (PDI) may act as a receptor or entry point for the delivery of the nitric oxide signal [16] [17] [18] . Both γ-GT [19] and PDI [20] have been shown to metabolise GSNO and mediate NO release. These metabolism studies, however, have generally been carried out using relatively high GSNO concentrations (high μM to mM range) and long time periods (minutes -hours) [21, 22] . The fact that GSNO inhibits platelet aggregation at very low concentrations (nM to low μM), and within seconds, suggests that its metabolism should be assessed over more relevant concentrations and time periods in order to understand its relevance to anti-platelet activity.
We have previously shown rapid metabolism of GSNO by platelets and megakaryocytes and the involvement of extracellular thiols in this process [23] . Here we extend these studies to report the role of PDI in rapid metabolism of GSNO and Snitroso human serum albumin (albSNO) at concentrations relevant to most published pharmacological studies and the relevance of this metabolism to NO delivery. We also report the effects of these interactions on PDI activity and its thiol redox status.
Experimental Procedures

Materials and reagents
Cell culture medium (RPMI-1640), phosphate buffered saline (PBS), penicillin, streptomycin and L-glutamine were obtained from Biowhittaker (Wokingham, UK).
Foetal calf serum (FCS) was purchased from Biowest (Ringmer, UK), MPB from All other chemicals were purchased from Sigma (Poole, UK).
Preparation of RSNO compounds
GSNO and S-nitrosocysteine (cysNO) were prepared as previously described [4] by nitrosation under acid conditions. Briefly, equal volumes of either glutathione or cysteine (20 mM) and sodium nitrite (20 mM) were incubated in the presence of 100 mM HCl on ice for 30 minutes in the presence of 1 mM EDTA. GSNO and cysNO were freshly prepared and stored in the dark on ice until used. Concentrations of GSNO and cysNO were estimated by absorbance at 334 nm using extinction coefficients of 0.85 and 0.75 mM -1 cm -1 , respectively.
AlbSNO was prepared by nitrosation of free thiols present on albumin. CysNO (20 mM) was incubated with albumin (1 mg/ml) in the dark for 1 hr. AlbSNO was then separated from low-molecular weight CysNO by passing it through Sephadex G-25 gel filtration column and collecting albumin fractions. The protein concentration of each fraction was measured by BCA protein kit and albSNO in each fraction was quantified using an NO electrode with reference to GSNO calibration curve. AlbSNO fractions were then pooled, quantified and stored at -20ºC until used.
Preparation of MEG-01 cell suspensions
The megakaryocyte cell line MEG-01 [24] was obtained from ATCC (Manassas, VA) and grown in RPMI-1640 medium supplemented with 10% v/v foetal calf serum (FCS), 50 IU/ml aqueous penicillin, 50 μg/ml streptomycin and 2 mM L-glutamine and incubated at 37ºC with a humidified atmosphere of 5% CO 2 . For experiments cells were suspended in HBS at a count of 3×10 9 l -1 .
Preparation of washed platelets
Washed platelets were prepared from informed healthy volunteers who had not received any medication known to alter platelet function for at least 2 weeks before study. Blood was anticoagulated with ACD and processed within 1 hour of collection. Washed platelets were separated from platelet rich plasma as previously described [25] and platelet count was adjusted to 200×10 9 l -1 by suspending in HEPES buffered saline (HBS), containing NaCl (140 mM), KCl (2.7 mM), Glucose (5mM), BSA (1mg/ml), CaCl 2 (1mM), MgCl 2 (1 mM) and HEPES (10 mM) (pH 7.3).
Cell mediated RSNO metabolism and effects of enzyme inhibitors
Cell mediated RSNO metabolism was analysed by treatment of MEG-01 cells with 1 μM GSNO or albSNO at 37ºC for 2 minutes, following which cells were centrifuged at 8300g for 30 seconds and residual RSNO in the supernatant was measured either using the fluorescent agent diaminonaphthaline [26] or by an electrochemical assay using an NO electrode (WPI, Stevenage, UK) [27] , calibrated against GSNO (0-2000 nM).
Control experiments were performed in the absence of MEG-01 cells.
The effect of different enzyme inhibitors and surface thiol blocking agents on RSNO metabolism was further investigated by pre-treatment of MEG-01 cells for 30 minutes at 37ºC. Bacitracin (5 mM) and acivicin (100 μM) were used to block PDI and γ-GT respectively, and an impermeable thiol blocking agent, 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) (100 μM) was used to modify extracellular thiol groups. RSNO decay, occurring after two minutes incubation with MEG-01 cells, was then measured.
Inhibition of platelet aggregation by RSNO
Platelet aggregation was performed using washed platelets suspended in HBS. Platelets 
PDI activity in cell supernatant
PDI has been shown to be released from platelets into the surrounding medium [28] . To measure PDI activity in MEG-01 supernatant, PDI-catalysed reduction of insulin was measured using a turbidometric assay [20] . MEG-01 cells were centrifuged at 8300g for 30 seconds to obtain supernatant for use in the insulin assay. Cell supernatant was added to insulin (250 μM) in the presence of glutathione (GSH) (500 μM) in HBS containing 2 mM EDTA, pH 7.0. The increase in turbidity was monitored at 650 nm over a period of 40 hours. PDI activity in the supernatant was also measured following the addition of GSNO (1 -500 μM).
Sulfhydryl labelling of intact MEG-01 cells
Cell surface thiol-containing proteins were labelled using the impermeable thiol specific probe, 3-N-maleimidylpropionyl-biotin (MPB) as described by Essex et al. [11] . MEG-01 cells were incubated with MPB (100 μM) for 30 minutes on a rotating wheel at room temperature. The labelling reaction was stopped by addition of GSH (200 μM) for 30 minutes and excess GSH was quenched using iodoacetamide (400 μM) for 10 minutes.
Cells were washed twice with HBS and resuspended in 0.5 ml of ice-cold 50 mM Tris/HCl buffer (pH 7.3) containing sucrose (250 mM), leupeptin (10 μM), PMSF (2 mM ) and EDTA (2 mM). Cells were lysed with three freeze/thaw cycles and centrifuged at 900g for 10 minutes to remove debris. The protein concentration of each sample was measured using BCA protein assay kit. Non-reducing SDS sample buffer was added to the cell lysate and the sample analysed using 10% SDS PAGE. Samples were transferred to a nitrocellulose membrane and biotinylated proteins were detected 11 using streptavidin-horseradish peroxidase and a chemiluminescent substrate. Negative control experiments were performed with MEG-01 cells by (1) omitting MPB, and (2) incubating cells with the thiol blocking agent 4,4'-dithiodipyridine (4-DP) (4 mM) for 30 minutes at 37ºC prior to addition of MPB. In both cases, there was a complete abolition of thiol labelling. To assess the effect of GSNO on cell surface thiols MEG-01 cells were incubated with GSNO (3.5 mM) prior to addition of MPB.
Immunoprecipitation of MEG-01 surface PDI
MEG-01 cells (3×10 9 l 
Statistical Analysis
Effects of various treatments on cyclic GMP accumulation and RSNO metabolism were analysed on log-transformed data by one-way ANOVA following by Student t test, using Bonferroni correction for multiple comparisons. significantly blocked cell-mediated removal of both GSNO (figure 1a) and albSNO (figure 1b). However, inhibition of γ-GT with acivicin (100 μM) failed to influence RSNO removal.
Results
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In separate experiments bacitracin and acivicin, at the stated concentrations, were
shown to completely inhibit the activity of authentic PDI, measured by turbidometric assay using insulin [20] and γ-GT, measured by colorimetric assay using γ-glutamyl paranitroaniline (data not shown). Cell viability, measured by trypan blue exclusion, was unaffected by treatment of cells with bacitracin, acivicin or DTNB at the stated concentrations (data not shown).
Inhibition of platelet aggregation by RSNO
The rapidity of GSNO as an antiplatelet agent was examined by platelet aggregation studies. Pre-incubation of platelets with 1 μM GSNO for as little as 5 seconds was sufficient to almost completely inhibit thrombin induced platelet aggregation compared with control (figure 2). In contrast, albSNO inhibited platelet aggregation only minimally even after 30 seconds pre-incubation.
Mechanism of intracellular NO delivery from GSNO
Intracellular accumulation of cyclic GMP was analysed as a measure of NO entry from GSNO and albSNO. GSNO incubation with MEG-01 for two minutes resulted in a significant cGMP accumulation (figure 3a), whereas albSNO failed to stimulate cGMP generation. Both bacitracin and DTNB, but not acivicin, significantly inhibited cGMP accumulation in response to GSNO (p < 0.05) (figure 3b). Control experiments omitting NO donors showed no effect of the various inhibitors on cGMP levels in their own right.
Detection of PDI activity in cell supernatant
PDI activity, detected using a turbidometric assay of insulin disulphide reduction was evident in MEG-01 cell supernatant. GSNO inhibited this activity, however very high concentrations were required to show this effect (figure 4).
Cell surface thiol modification by GSNO
Our experiments suggested that GSNO, but not albSNO, was capable of delivering NO 
Identification of PDI as a target for redox modification by GSNO
To determine whether PDI is a one of the target proteins modified by GSNO, MEG-01 cells were labelled with MPB and RL 90 anti-PDI antibody was then used to immunoprecipitate PDI. Pretreatment of MEG-01 cells with GSNO (0.5 -5 mM)
resulted in a loss of thiol labelling of PDI in a concentration dependent manner ( figure   6 ). Subsequent treatment with GSH resulted in a restoration of thiol labelling, indicating that the modification was reversible ( figure 7 ).
Discussion
Our study shows that cell surface thiols and protein disulphide isomerase are required for NO delivery from GSNO into MEG-01 cells. Both GSNO and albSNO were rapidly metabolized by MEG-01 cells, however there was a discrepancy between albSNO metabolism and its NO signalling function. We have demonstrated cell surface thiol modification by GSNO and identified PDI as one of the target proteins. This is consistent with previous suggestions that PDI-catalysed S-nitrosation of cell surface thiols is a mechanism of nitric oxide delivery from GSNO [5, 18] . In most published studies of cell mediated GSNO metabolism, relatively high concentrations and long time periods have been employed, yet even at concentrations as low as 1 μM, inhibition of platelet aggregation is evident within seconds. It is therefore difficult to assess the relevance of such studies to the anti-platelet actions of GSNO.
Here, we found that cell mediated decay of 1 μM GSNO was evident within two minutes. This rapid GSNO removal was significantly inhibited both by modification of cell surface thiols with DTNB, and by inhibition of cell surface PDI with bacitracin.
Exposure of cells to acivicin to block γGT failed to influence GSNO removal, indicating that cell surface thiols and PDI, but not γGT, are required for rapid metabolism of GSNO. This is consistent with recent literature demonstrating PDI mediated GSNO consumption by platelets [20] and suggests that GSNO consumption may be relevant to its anti-platelet function. Ramachandran et al. [18] have provided evidence that NO released from impermeable RSNO molecules by cell surface PDI reacts with oxygen within the hydrophobic environment of the lipid membrane to produce N 2 O 3 , which then nitrosates intracellular thiol-containing molecules. Our data indicate that this, or a similar, pathway may be involved in the delivery of NO from GSNO onto the haem group of soluble guanylyl cyclase so as to stimulate generation of cyclic GMP. PDI inhibitors blocked this cyclic GMP accumulation significantly but not completely, implying the existence of alternative pathways for NO delivery.
In contrast, the fate of the removed fraction of albSNO, and its relevance to NO signalling, are not clear. We observed that albSNO was metabolized in a similar way to
GSNO, yet failed to inhibit platelet aggregation or stimulate intracellular cGMP accumulation. This suggests a discrepancy between the metabolism phenomenon, and subsequent signalling events. It has been documented that NO delivery into cells from protein RSNO molecules, such as albSNO, requires a prior transfer of NO to a low molecular weight thiol, via transnitrosation [8, 9] . Our experiments were performed in the absence of added thiol and this may explain why metabolism of albSNO was not accompanied by cGMP accumulation or inhibition of platelet aggregation.
The involvement of PDI in transferring NO across the plasma membrane raises the question of how this process affects the function of PDI itself. PDI activity is dependent on its vicinal free thiol groups at the active site [29] which themselves may act as a target for nitrosation. We studied changes brought about by GSNO in thiol redox state of MEG-01 cell surface proteins. Consistent with earlier reports [10, 11] a number of such proteins were detectable by western blotting using MPB, an impermeable thiol specific probe. Cell treatment with GSNO caused a loss of thiol reactivity on most, but not all, proteins suggesting a selective process of GSNO-mediated thiol redox modification. Thiol modification of PDI itself was demonstrated using immunoprecipitation with a specific antibody, and this was GSNO concentrationdependent. Subsequent addition of GSH led to restoration of thiol labelling, indicating that the GSNO-mediated thiol modification was reversible. It has been discussed that in the presence of sulphydryl compounds S-nitrosated proteins can undergo either transnitrosation, to restore the reduced thiol state, or S-thiolation reactions, yielding disulphide and nitroxyl [30, 31] . Our results indicate that, under the conditions used, the former reaction was predominant.
PDI is known to be present on the surface of platelets and to be released during platelet activation [28, 32] . We also found PDI activity to be released from MEG-01 cells, and inhibited by GSNO, again consistent with an earlier report [20] . Thus the involvement of PDI in mediating NO transfer results in thiol modification and enzyme inactivation.
The mechanisms employed to restore the redox state of active site thiols in PDI following interaction with GSNO are not yet clear. Burgess et al. [10] showed that the redox state of platelet surface PDI was refractory to extracellular reducing agents, but discussed the possibility that it might be controlled by a plasma membrane electron transfer system such as NAD(P)H oxidase.
PDI activity was inhibited by interaction with GSNO, although high concentrations were required to show this effect. Our findings are consistent with those of Root et al.
[20] who showed full inhibition of PDI was not achieved by GSNO at concentrations lower than 500 μM. We also found that very high concentrations of GSNO were needed to demonstrate PDI thiol modification. In view of the fact that GSNO suppresses platelet activation in the nanomolar to micromolar range, it is clear that further investigations will be required to establish the physiological relevance of these interactions.
The integrin family of cell surface adhesive receptors mediates platelet aggregation by up-regulating their affinity state for ligand binding. Free thiols become available on the platelet surface upon activation [10] and those present on integrin α IIb β 3 provide a direct target for redox modification [33] . influences platelet adhesive function and any agent that modifies this redox state may interfere with platelet aggregation. Our data are consistent with a model in which GSNO mediates its actions by both cGMP-dependent and independent pathways.
Targeting of NO to cell surface free thiols facilitates its entry into cells and its interaction with soluble guanylyl cyclase to promote cGMP-dependent pathways.
cGMP-independent actions may be mediated by thiol modification of surface targets such as PDI, thus inhibiting activation of α IIb β 3 . This does not exclude other mechanisms of cGMP-independent action such as inhibition of intracellular calcium entry [37] or direct nitrosation of α IIb β 3 [33, 38] .
Overall, our data show that PDI is involved in the rapid metabolism of RSNOs and in Cell surface thiol labelling with MPB was performed as previously described. Cells were treated with graded GSNO concentrations (0 -5 mM) prior to labelling with MPB.
Cells were then lysed and PDI was immunoprecipitated using a monoclonal antibody (RL 90) (4.2 μg ml -1 ). Control experiments were performed using an isotype control antibody. Results shown are representative of 3 similar experiments. 
